RxDoctor Payments Data

Mike Wei, MD

Gastroenterology · Stanford, CANPI 1417311408

Payments from drug & device makers

$381,751in general payments, 2019–2025

Across 37 payments — averaging $10,318 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Capsovision, Inc.$334K
  • Conmed Corporation$33K
  • Neptune Medical Inc.$11K
  • Endogastric Solutions, Inc$2K
  • Ovesco Endoscopy USA, Inc.$935
  • Olympus America Inc.$149
  • plus $288 from 3 others

What the payments were for

  • Consulting fees$344,88690%
  • Grants$33,3339%
  • Travel & lodging$2,9721%
  • Food & beverage$5600%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Capsovision, Inc.26$334,086
Conmed Corporation1$33,333
Neptune Medical Inc.2$10,800
Endogastric Solutions, Inc2$2,160
Ovesco Endoscopy USA, Inc.1$935
Olympus America Inc.1$149
Boston Scientific2$136
AbbVie1$122
Apollo Endosurgery US Inc1$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$381,751 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$151,588
Medicare patients
336
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide26$21,497
Dexlansoprazole DrDexlansoprazole30$7,194
Esomeprazole Magnesium53$6,453
Sucralfate13$3,359
Colesevelam Hcl12$1,614
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg76$1,609
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl70$1,317
Omeprazole102$1,271
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates16$1,218
Famotidine83$1,115
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl27$546
Pantoprazole Sodium16$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$122$21,49726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →